Recordati traded at 44.81 this Monday March 16th, decreasing 0.67 or 1.47 percent since the previous trading session. Looking back, over the last four weeks, Recordati lost 5.34 percent. Over the last 12 months, its price fell by 16.01 percent. Looking ahead, we forecast Recordati to be priced at 44.07 by the end of this quarter and at 40.10 in one year, according to Trading Economics global macro models projections and analysts expectations.
Recordati Industria Chimica e Farmaceutica SpA is an Italy-based group engaged in the research, development, manufacture and marketing of pharmaceuticals. It promotes a wide range of pharmaceuticals, both proprietary and under license, in a number of therapeutic areas, such as Antibiotics and Antiviral, Cardiovascular, Central nervous system, Dermatological, Gastroenterology, Genital-urinary system, Muscular-skeletal disorders and pain therapy, Obstetrics and Gynecology and over the counter (OTC) pharmaceuticals. The Company is engaged in the research and development of new drug entities within the cardiovascular and urogenital therapeutic areas and of treatments for rare diseases. It’s product is ZANIDIP, a latest generation calcium-channel blocker for the treatment hypertension. It operates through Italchimici SpA, Pro Farma AG and North American marketing rights to Cystadane. The Company owns and operates through Natural Point srl also in the food supplement sector.